- Details
- Description
Packaging Size:
Commonly 14 or 56 tablets; some markets also have 168-tablet multipacks.
Strength:
5 mg
Composition:
Ruxolitinib 5 mg (as ruxolitinib phosphate) per tablet.
Treatment:
Myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease, depending on indication and local approval.
Form:
Tablet
Brand:
Jakavi
Quantity Unit:
1 tablet
Manufacturer:
Novartis; manufacturing sites may vary by market.
Jakavi 5 mg (Ruxolitinib) is a prescription medicine used to treat myelofibrosis and polycythemia vera. It works by selectively inhibiting the JAK1 and JAK2 enzymes, helping control abnormal blood-cell production and reduce symptoms such as enlarged spleen, fatigue, and other disease-related discomfort. It is generally used under specialist supervision with regular monitoring.
